Rosen B - Search Results

1

Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years.

Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, Colgan T, Chapman W, Shaw P. Covens A, et al. Among authors: rosen b. Gynecol Oncol. 2001 May;81(2):133-7. doi: 10.1006/gyno.2001.6158. Gynecol Oncol. 2001. PMID: 11330939

2

Concurrent radiation and chemotherapy in vulvar carcinoma.

Thomas G, Dembo A, DePetrillo A, Pringle J, Ackerman I, Bryson P, Balogh J, Osborne R, Rosen B, Fyles A. Thomas G, et al. Among authors: rosen b. Gynecol Oncol. 1989 Sep;34(3):263-7. doi: 10.1016/0090-8258(89)90157-1. Gynecol Oncol. 1989. PMID: 2504651

3

High-dose methotrexate for gestational trophoblastic disease.

Elit L, Covens A, Osborne R, Gerulath A, Murphy J, Rosen B, Sturgeon J. Elit L, et al. Among authors: rosen b. Gynecol Oncol. 1994 Sep;54(3):282-7. doi: 10.1006/gyno.1994.1211. Gynecol Oncol. 1994. PMID: 7522198 Clinical Trial.

4

Meta-analysis comparing cisplatin total dose intensity and survival.

Ben-David Y, Rosen B, Franssen E, Einarson T, Szyfer I. Ben-David Y, et al. Among authors: rosen b. Gynecol Oncol. 1995 Oct;59(1):93-101. doi: 10.1006/gyno.1995.1273. Gynecol Oncol. 1995. PMID: 7557623

5

Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study.

LoCoco S, Covens A, Carney M, Franssen E, Dogde R, Rosen B, Osborne R, Kerr I, Buckman R, Soper J, et al. LoCoco S, et al. Among authors: rosen b. Gynecol Oncol. 1995 Nov;59(2):194-9. doi: 10.1006/gyno.1995.0007. Gynecol Oncol. 1995. PMID: 7590472

6

Differences in the morbidity of radical hysterectomy between gynecological oncologists.

Covens A, Rosen B, Gibbons A, Osborne R, Murphy J, DePetrillo A, Lickrish G, Shaw P, Colgan T. Covens A, et al. Among authors: rosen b. Gynecol Oncol. 1993 Oct;51(1):39-45. doi: 10.1006/gyno.1993.1243. Gynecol Oncol. 1993. PMID: 8244172

7

Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.

Elit LM, Levine MN, Gafni A, Whelan TJ, Doig G, Streiner DL, Rosen B. Elit LM, et al. Among authors: rosen b. Gynecol Oncol. 1996 Sep;62(3):329-35. doi: 10.1006/gyno.1996.0244. Gynecol Oncol. 1996. PMID: 8812525

8

Psychological impact of screening for familial ovarian cancer: reactions to initial assessment.

Erlick Robinson G, Rosen BP, Bradley LN, Rockert WG, Carr ML, Cole DE, Murphy KJ. Erlick Robinson G, et al. Among authors: rosen bp. Gynecol Oncol. 1997 May;65(2):197-205. doi: 10.1006/gyno.1997.4686. Gynecol Oncol. 1997. PMID: 9159325

9

The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk.

Rosen B, Irvine J, Ritvo P, Shapiro H, Stewart D, Reynolds K, Robinson G, Thomas J, Neuman J, Murphy J. Rosen B, et al. Fertil Steril. 1997 Jul;68(1):90-4. doi: 10.1016/s0015-0282(97)81481-1. Fertil Steril. 1997. PMID: 9207590 Free article.

10

Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias.

Arab S, Russel E, Chapman WB, Rosen B, Lingwood CA. Arab S, et al. Among authors: rosen b. Oncol Res. 1997;9(10):553-63. Oncol Res. 1997. PMID: 9507533

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,930 results

Search Page

Filters